ALLO

#2706
Allogene Therapeutics, Inc. - Common Stock
2.0 2 USD
-0.03%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.02
2.02
Intervallo Annuale
1.04
4.46
Variazione giornaliera
-3.35%
Variazione Mensile
+2.54%
Variazione di 6 mesi
-24.34%
Variazione Annuale
+80.36%
Chiusura Precedente
2.0 9
Open
2.0 2
Minimo
2.0 2
Massimo
2.0 2
Volume
81
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Allogene Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Allogene Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Allogene Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Allogene Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Allogene Therapeutics, Inc. current report, Q1 FY2026
8-K

Allogene Therapeutics, Inc. current report, Q2 FY2026

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Allogene Therapeutics, Inc. on May 28, 2026. The filing discloses a significant change in executive leadership and board composition effective July 1, 2026.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements.

Material Changes

  • Executive Leadership Transition: Zachary Roberts, M.D., Ph.D., was appointed President and Chief Executive Officer, replacing David Chang, M.D., Ph.D.
  • Effective Dates: Dr. Roberts' new roles begin July 1, 2026. Dr. Chang's last day as CEO is June 30, 2026.
  • Board Composition: Dr. Roberts was appointed to the Board as a Class I director effective July 1, 2026. Dr. Chang will remain on the Board as a non-employee director.
  • Interim Roles: Dr. Roberts will continue serving as Chief Medical Officer on an interim basis following the Effective Date.

Compensation and Outlook

The Board approved the following compensatory arrangements for Dr. Roberts, effective July 1, 2026:

  • Base Salary: $680,000 annualized.
  • Cash Incentive: Annual target performance cash incentive of 60% of base salary.
  • Equity Awards:
    • Option to purchase 476,190 shares of common stock (vesting: 25% at one-year anniversary, remainder over 36 monthly installments).
    • Restricted Stock Units (RSUs) for 134,530 shares (vesting: four equal annual installments).
  • Severance: Dr. Roberts is entitled to severance and change of control benefits under the Company's Severance Plan. Dr. Chang is eligible for severance benefits under the same plan upon conclusion of his service as CEO.

The filing does not contain specific financial guidance, risk factors, or management commentary regarding the company's operational outlook beyond the leadership transition.

Investor Verification Checklist

  • Verify the terms of the "Change in Control and Severance Benefit Plan" referenced in the April 30, 2026 Proxy Statement to understand potential payout obligations for both outgoing and incoming CEOs.
  • Review Dr. Roberts' prior experience at Instil Bio, Kite, and Amgen to assess strategic alignment with Allogene's pipeline.
  • Monitor the transition period between June 30 and July 1, 2026, for any interim operational announcements.
  • Check subsequent filings for the impact of this leadership change on the company's clinical development timelines and capital allocation strategy.

Notizie